Input | Mean (range) | Reference |
---|---|---|
Epidemiological and clinical data | ||
Population size by age | see reference | [14] |
IFR in Germany | 0.0075 (0.005 – 0.01) | [48] |
CFR in Germany | ||
Total population | 0.042 | |
0-9 years | 0.00009 | |
10-19 years | 0.00005 | |
20-29 years | 0.00022 | ; |
30-39 years | 0.00070 | |
40-49 years | 0.0025 | ; |
50-59 years | 0.0095 | |
60-69 years | 0.048 | |
70-79 years | 0.16 | |
80-89 years | 0.28 | ; |
90+ years | 0.33 | |
Probability of ICU indication | 0.04 (0.04 – 0.08) | |
False-positive ICU admissions | 0.1 (0.1 – 0.2) | [2] |
CFR in the ICU | 0.24 (0.23 – 0.25) | |
CFR one year post ICU discharge | 0.59 (0.47 – 0.73) | [8] |
Herd protection threshold | 0.70 (0.60 – 0.70) | [28] |
Vaccine efficacy | 0.5 – 1.0 | [17] |
Immunity following one vaccination, years | 5 (1 – 5) | |
Cost data | ||
GDP reduction per pandemic wave, % | 1.8 | |
GDP reduction without a second wave, % | 5.0 | |
GDP drop attributable to shutdown versus voluntary restrictions, % | 100 (10 – 100) | Estimate |
German federal government subsidy for vaccine development | 750,000,000 | [16] |
Contribution of a shutdown to GDP reduction, % | 30 (10 – 30) | [38] |
Vaccine costs per individual, € | 8.47 | [10] |
Vaccination costs per individual, € | 7.95 | [29] |